MX2024006053A - Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13. - Google Patents

Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13.

Info

Publication number
MX2024006053A
MX2024006053A MX2024006053A MX2024006053A MX2024006053A MX 2024006053 A MX2024006053 A MX 2024006053A MX 2024006053 A MX2024006053 A MX 2024006053A MX 2024006053 A MX2024006053 A MX 2024006053A MX 2024006053 A MX2024006053 A MX 2024006053A
Authority
MX
Mexico
Prior art keywords
methods
antagonist
administering
attenuating
atopic march
Prior art date
Application number
MX2024006053A
Other languages
English (en)
Inventor
Gregory Geba
Dateng Li
Judy Xiang Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2024006053A publication Critical patent/MX2024006053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para prevenir el desarrollo de una nueva condición alérgica o el empeoramiento de una condición alérgica concomitante existente en un sujeto que tiene una enfermedad atópica tal como dermatitis atópica. En un aspecto, los métodos comprenden administrar al sujeto un plan de terapia de un antagonista de IL-4/IL-13, tal como un anticuerpo anti-IL-4R o fragmento del mismo de unión al antígeno.
MX2024006053A 2021-12-30 2022-12-29 Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13. MX2024006053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163295113P 2021-12-30 2021-12-30
PCT/US2022/082535 WO2023130010A1 (en) 2021-12-30 2022-12-29 Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Publications (1)

Publication Number Publication Date
MX2024006053A true MX2024006053A (es) 2024-07-29

Family

ID=85199428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006053A MX2024006053A (es) 2021-12-30 2022-12-29 Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13.

Country Status (9)

Country Link
US (1) US20230220089A1 (es)
EP (1) EP4457245A1 (es)
KR (1) KR20240135618A (es)
CN (1) CN118355034A (es)
AU (1) AU2022425608A1 (es)
CA (1) CA3241374A1 (es)
IL (1) IL313897A (es)
MX (1) MX2024006053A (es)
WO (1) WO2023130010A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
MX361174B (es) 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
WO2006124451A2 (en) 2005-05-11 2006-11-23 Centocor, Inc. Anti-il-13 antibodies, compositions, methods and uses
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
EP2004691A1 (en) 2006-03-22 2008-12-24 Apogenix GmbH Antibody specific for human il-4 for the treament of cancer
KR101676269B1 (ko) 2006-09-08 2016-11-15 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
PT2069403E (pt) 2006-10-02 2014-07-18 Regeneron Pharma Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EA028945B1 (ru) 2010-10-06 2018-01-31 Ридженерон Фармасьютикалз, Инк. СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα)
PL2627673T3 (pl) 2010-10-15 2018-01-31 Medimmune Ltd Terapie poprawiające funkcje płuc
JP2016522168A (ja) 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CN111686247B (zh) 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
CN111592597B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
BR112022015363A2 (pt) * 2020-03-27 2022-09-20 Regeneron Pharma Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
WO2022052974A1 (en) 2020-09-10 2022-03-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof
EP4019547A1 (en) 2020-12-23 2022-06-29 Numab Therapeutics AG Multispecific antibodies having specificity for il-4r and il-31
JP2024501657A (ja) 2020-12-23 2024-01-15 ヌマブ セラピューティクス アクチェンゲゼルシャフト Ｉｌ－３１に結合する抗体可変ドメイン

Also Published As

Publication number Publication date
IL313897A (en) 2024-08-01
KR20240135618A (ko) 2024-09-11
CN118355034A (zh) 2024-07-16
WO2023130010A1 (en) 2023-07-06
US20230220089A1 (en) 2023-07-13
WO2023130010A8 (en) 2023-08-10
AU2022425608A1 (en) 2024-08-15
EP4457245A1 (en) 2024-11-06
CA3241374A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
PH12021550023A1 (en) Humanized anti-tau antibodies
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX2022001247A (es) Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.
WO2013119716A8 (en) Compositions and methods for using csf1r inhibitors
EA201590210A1 (ru) Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
BR112021019135A2 (pt) Anticorpo anticlaudina 18.2 e aplicação do mesmo
NZ630363A (en) Anti-kit antibodies and uses thereof
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
NZ709997A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX357837B (es) Métodos para inhibir el crecimiento tumoral mediante receptor il - 6 antagonizante.
BR112015021979A2 (pt) Anticorpos humanos para grem1
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
MX2015005481A (es) Metodos para tratar enfermedades asociadas con s. aureus.
MX2016013372A (es) Metodos de tratar selectivamente el asma utilizando antagonistas de il-13.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
MX2022011730A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2022008255A (es) Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofilica.
MX2024006053A (es) Metodos para atenuar la marcha atopica administrando un antagonista de il-4/il-13.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
BR112016030568A2 (pt) anticorpos biespecíficos anti-il4-il13
MX2024002072A (es) Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.